Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence

Launched by UNIVERSITY OF TENNESSEE · Dec 3, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how well patients with certain blood cancers, like chronic myeloid leukemia and multiple myeloma, manage their medications when they also have other chronic conditions, such as diabetes or high blood pressure. The goal is to see if working together with pharmacists in both cancer care and general health can help improve how patients take their medications and manage their health overall. This is a pilot study, which means it’s a smaller-scale investigation that will help researchers gather information for a larger study later on.

To be eligible for this trial, participants need to be receiving cancer treatment at Vanderbilt University Medical Center and have a diagnosis of one of the specified blood cancers. They should also have at least two chronic health conditions and be starting a new oral cancer medication. Participants will need to be comfortable signing consent forms and will be involved in discussions around their medication and health management. The research team will provide guidance and support throughout the study to help ensure participants understand their treatments and how to take them properly.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Receiving cancer care at Vanderbilt University Medical Center
• • Diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), chronic myeloid leukemia (CML), or multiple myeloma (MM)
• • Initiating an oral anticancer agent, either for the first time or a change from previous oral agent
• • Diagnosis of 2 chronic conditions, including at least one of the following: diabetes, hypertension, hyperlipidemia, congestive heart failure, depression/anxiety, gastroesophageal reflux disease, and/or chronic obstructive pulmonary disease
• • Patients taking at least two chronic medications, including at least one medication for one of the conditions listed above.
• • Willing and able to sign informed consent.
• Exclusion Criteria:
• • Cannot communicate in English
• • Concurrent diagnosis of type 1 diabetes or human immunodeficiency virus